EUVIMEDEUVIMED entdecken
Open Access

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo

Fei Gao iD, Holly Janes, Susan Buchbinder, Deborah Donnell

Statistics in Medicine · 2025

DOI: 10.1002/sim.70022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Fei Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics, Bioinformatics and Epidemiology Program, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Research Design, Controlled Clinical Trials as Topic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the quest for enhanced HIV prevention methods, the advent of antiretroviral drugs as pre‐exposure prophylaxis (PrEP) has marked a significant stride forward. However, the ethical challenges in conducting placebo‐controlled trials for new PrEP agents against a backdrop of highly effective existing PrEP options necessitate innovative approaches. This manuscript delves into the design and implementation of active‐controlled trials that incorporate a counterfactual placebo estimate—a theoretical estimate of what HIV incidence would have been without effective prevention. We introduce a novel statistical framework for regulatory approval of new PrEP agents, predicated on the assumption of an available and consistent counterfactual placebo estimate. Our approach aims to assess the absolute efficacy (i.e., against placebo) of the new PrEP agent relative to the absolute efficacy of the active control. We propose a two‐step procedure for hypothesis testing and further develop an approach that addresses potential biases inherent in non‐randomized comparisons to counterfactual placebos. By exploring different scenarios with moderately and highly effective active controls and counterfactual placebo estimates from various sources, we demonstrate how our design can significantly reduce sample sizes compared to traditional non‐inferiority trials and offer a robust framework for evaluating new PrEP agents. This work contributes to the methodological repertoire for HIV prevention trials and underscores the importance of adaptability in the face of ethical and practical challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisResearch DesignControlled Clinical Trials as TopicHumansPlacebosAnti-HIV AgentsModels, StatisticalSample SizeComputer Simulation

Stichwörter der Autor:innen

HIV preventionactive‐controlled trialscounterfactual placebopre‐exposure prophylaxisrelative absolute efficacysample size calculation

Substanzen

PlacebosAnti-HIV Agents

Autor:innen und Institutionen

  • Biostatistics, Bioinformatics and Epidemiology Program, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California, USA.

ORCID-Profile: Fei Gao

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Gao, F., Janes, H., Buchbinder, S., & Donnell, D. (2025). Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo. Statistics in Medicine. https://doi.org/10.1002/sim.70022

Vancouver

Gao F, Janes H, Buchbinder S, Donnell D. Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo. Statistics in Medicine. 2025. doi:10.1002/sim.70022

BibTeX
@article{Gao2025,
  author = {Gao, Fei and Janes, Holly and Buchbinder, Susan and Donnell, Deborah},
  title = {Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70022}
}
Kostenlos starten →